Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (not Savara Inc.) on October 29, 2015. The filing addresses Item 5.02 regarding the election of a new director and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the election of Matthew Pauls to the Board of Directors, effective immediately on October 29, 2015. The Board determined Mr. Pauls to be an "independent director."
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of the new director's compensation package:
- Cash Retainer: An annual cash retainer of $35,000, payable in equal quarterly installments and pro-rated for the fourth quarter of 2015.
- Stock Options: Two "inducement options" were granted under the 2015 Omnibus Incentive Plan:
- Option 1: To purchase up to 64,791 shares of common stock.
- Option 2: To purchase up to 37,794 shares of common stock.
- Indemnification: An Indemnification Agreement was entered into, providing for indemnification and advancement of litigation expenses to the fullest extent permitted by law.
The filing does not contain financial guidance, outlook, or specific risk factors beyond standard legal indemnification terms.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2015 Omnibus Incentive Plan to assess the impact of the 102,585 new option grants.
- Review the definitive proxy statement filed on April 29, 2015, for the full terms of the non-employee director compensation policy.
- Confirm the pro-rated cash payment calculation for the fourth quarter of 2015.
- Note the discrepancy between the requested company name (Savara Inc.) and the actual registrant (Mast Therapeutics, Inc.).